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Abstract
Background: Most systematic reviews have explored the efficacy of treatments on symptoms associated with post-traumatic
stress disorder (PTSD), which is a chronic and often disabling condition. Previous network meta-analysis (NMA) had limitations such
as focusing on pharmacological or psychotherapies. Our review is aims to explore the relative effectiveness of both pharmacological
and psychotherapies and we will establish the differential efficacy of interventions for PTSD in consideration of both symptom
reduction and functional recovery.
Methods:Wewill conduct a network meta-analysis of randomized controlled trials evaluating treatment interventions for PTSD.We
will systematically search Medline, PILOT, Embase, CINHAL, AMED, Psychinfo, Health Star, DARE and CENTRAL to identify trials
that: (1) enroll adult patients with PTSD, and (2) randomize them to alternative interventions or an intervention and a placebo/sham
arm. Independent reviewers will screen trials for eligibility, assess risk of bias using a modified Cochrane instrument, and extract data.
Our outcomes of interest include PTSD symptom reduction, quality of life, functional recovery, social and occupational impairment,
return to work and all-cause drop outs.
Results:We will conduct frequentist random-effects network meta-analysis to assess relative effects of competing interventions.
We will use a priori hypotheses to explore heterogeneity between studies, and assess the certainty of evidence using the GRADE
approach.
Conclusion: This network meta-analysis will determine the comparative effectiveness of therapeutic options for PTSD on both
symptom reduction and functional recovery. Our results will be helpful to clinicians and patients with PTSD, by providing a high-quality
evidence synthesis to guide shared-care decision making.
Abbreviations: CAPS = clinician-administered PTSD scale, CI = confidence interval, DSM = diagnostic and statistical manual of
mental disorders, GRADE = grading of recommendations assessment, development, and evaluation, MCS = mental component
summary, NMA = network meta-analysis, PCS = physical component summary, PTSD = post-traumatic stress disorder, SUCRA =
surface under the cumulative ranking curve.
Keywords: CAPS, disability, functions, network meta-analysis, PTSD, quality of life, return to work
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Post-traumatic stress disorder (PTSD) results from experiencing
or witnessing an emotionally traumatic event that is perceived to
present a threat to the life or physical integrity of one’s self or
others. PTSD is defined by 8 criteria (Table 1),[1,2] including




(3) negative alterations in cognitions and mood, and
(4) alterations in arousal and reactivity.
The sixth criterion requires that symptoms have been present for
>1month; the seventh assesses functioning (ie, symptoms interfere
with the ability to go about normal daily tasks); and the eighth
criterion is that symptoms are not attributable to another medical
condition.[3] Whereas some symptoms associated with PTSD (eg,
hypervigilance) function to maintain an ongoing sense that the
inciting event could happen again, which in turn, maintains fear
and avoidance,[4] others are associated with persistent feelings of
shame and guilt (eg, negative-trauma related emotions). The
diagnostic and statistical manual of mental disorders (DSM-5)[3]
also includes a dissociative subtype of PTSD, in recognition that
15% to 30% of patients with PTSD presents with symptoms of
depersonalization and derealization.[5–15]
The lifetime prevalence of PTSDamong the general public is 8%
to9%,[16–18] andbetweenaquarter anda thirdofworkers exposed
to traumatic events develop symptoms of PTSD.[19,20] Patients
suffering with PTSD experience social impairment, high absentee-
ism, unemployment[21–27] andwork-related disability, particularly
when completing tasks requiring high concentration and cognitive
demands.[24–25] According to a 2016 review, 2.5 million of the
general population and 70,000 first responders in Canada would
suffer with PTSD in at some point in their lifetime.[28] In a
retrospective study of 44 PTSD claims awarded by the Workers
Compensation Board of British Columbia, Canada, only 43% of
disabled workers returned to their previous job 4 years after their
trauma, 23% returned to alternate employment, and 34%did not
returned to any type of work.[29] Similarly, a prospective study of
94 PTSD patients in Ontario, Canada, found 57% had not
returned towork in any capacity 9months after theirmotor vehicle
accident; among the 43% who had, a little more than half (57%)
required job modification.[30]
There is uncertainty regarding what treatments are most
effective for facilitating return-to-work among traumatized
workers. Existing systematic reviews focus on the effect of
selected therapies instead of exploring the relative effectiveness of
competing therapies, and on amelioration of PTSD symptoms
versus functional recovery.[31–37] A previous network meta-
analysis (NMA) of pharmacological treatments for PTSD[38] has
a number of limitations, including:
(1) an outdated search (February 2016),
(2) consideration of pharmacologic therapies only,
(3) narrow focus on exploring treatment effects for only
symptom reduction and all-cause drop-outs, and
(4) use of the surface under the cumulative ranking curve
(SUCRA) approach to rank interventions – an approach that
does not consider the quality of evidence, or the estimates of
precision around treatment effects.
Another NMA[39] was similarly limited by a narrow focus
only on psychotherapeutic approaches, an outdated search
(January 2011), time-restricted search strategies (1980–2010),
inclusion of trials with patients who had subclinical or sub-
threshold PTSD and treatment effects limited to only symptom
reduction.
Table 1
DSM 5-criteria for PTSD with description.
Diagnostic criteria Description
Criteria A (1 symptom
required)
Exposure to trauma Exposure to event (involved or witnessed) that posed a threat of death, serious injury, or sexual violence.
Learning that a close relative or close friend was exposed to trauma.
Person experiences helplessness, horror, and intense fear to aversive details, which may be part of their work.





Recurrent intrusive thoughts or recollection of memories of the traumatic event, nightmares, flash backs and
intense fear/ reaction to both internal and external reminders
Criteria C (1 required) Avoidance Persistent avoidance of stimulus associated with trauma such as avoiding distressing memories, or avoiding
people, places, conversations, activities or situations
Criteria D
(2 symptom required)
Cognitive deficit Persistent numbing such as alteration in mood, cognitions that are associated with traumatic event such as
inability to recall key features of the traumatic event, negative thoughts about one self, persistent negative
trauma-related emotions, diminished interest
Criteria E
(2 symptom required)
Hyper arousal Sleep impairment, nightmares and reactivity associated with the traumatic event, irritability, aggressive behavior,
exaggerated startle response
Criteria F Duration Symptoms are present for more than 1 month
Criteria G Functional Impairment Symptoms are associated with persistent functional impairment, social and occupational impairment
Criteria H Exclusion Not due to medication, substance use or illness
Two specifications Dissociative features Depersonalization: persistent feeling of detachment from one’s mental processes or body as if one were in dream
Derealization: experiencing distortion or detachment from reality
With delayed specifications Full diagnostic criteria are not met until at least 6 months after the event
This table is adapted from the DSM 5 criteria from the American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing; 2013.
DSM = diagnostic and statistical manual of mental disorders, PTSD = post-traumatic stress disorder.
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As existing reviews of treatment for PTSD have largely
focussed on individual treatment’s effect on symptom reduction
and none have compared all treatments against each other. Due
to which there exist considerable uncertainty regarding what
treatments are effective for promoting symptom control and
functional recovery. Our proposed NMA will evaluate all
treatments for PTSD, provide relative effectiveness of treatments,
and evaluate the quality of the evidence in a thorough and
consistent manner using the grading of recommendations
assessment, development, and evaluation (GRADE) approach.
2. Methods
We registered our protocol on PROSPERO (CRD42018072682).
Our review will conform to the PRISMA Extension Statement for
Reporting of Systematic Reviews Incorporating Network Meta-
analyses of Health Care Interventions.[40]
2.1. Search strategy
We identified all relevant randomized trials, in any language,
through a systematic search of published international literature
on traumatic stress, CINAHL, EMBASE, MEDLINE, AMED
allied and complementary medicine, HealthSTAR, database of
abstracts of reviews of effects, PsychINFO, and the Cochrane
Central Registry of Controlled Trials (Appendix#1). An experi-
enced medical librarian refined our search strategy for each
database. Reviewers scanned the bibliographies of all eligible
trials and other relevant publications for additional trials. We did
not have any language restriction.
2.2. Eligibility criteria and study selection
Trials were eligible if they enrolled adult patients diagnosed with
primary or secondary PTSD according to operationalized criteria
such as DSM criteria, international classification of diseases
criteria, or clinician diagnosed and randomized them to any
pharmacologic (monotherapy or add-on therapy) or nonphar-
macologic treatment strategy compared to an alternative
treatment, their combinations, placebo or control. Eligible
pharmacologic interventions included but were not restricted
to antidepressants such as selective serotonin inhibitor, nonse-
lective serotonin inhibitors, anxiyoltics, antipsychotics, and
antiepileptics or mood stabilizers. Eligible nonpharmacologic
interventions included but were not restricted to: cognitive
behavioral therapy, exposure therapy, yoga, supportive therapy,
and eye movement desensitization and reprocessing.
We will exclude trials with less than 10 participants per arm,
pilot or feasibility or preliminary studies, and cross-over trials.We
will also exclude trials in which the population does not constitute
100% PTSD patients including sub-threshold or subclinical or
partial PTSD. We will also exclude studies that enrolled patients
suffering with acute stress disorders. Conference abstracts and
rarely used interventions or interventions that are discontinueddue
to serious adverse effects (suchasNefazadone,Brofaromine) rarely
used for interventions in North America will be excluded.
Using standardized forms, reviewers will work independently
in duplicate to screen title and abstracts, and the full text of all
potentially eligible studies. Before starting literature screening, all
reviewers will complete a pilot exercise to ensure understanding
of the process and improve reliability. Any discrepancies will be
resolved through consensus between reviewers or with the help of
an adjudicator.
2.3. Data abstraction
To help ensure the reliability of independent data extraction, we
will begin by piloting our data extraction form and then we will
conduct calibration exercises between reviewers. Data abstrac-
tion will be guided by a detailed instruction manual generated
from our piloting and calibration exercises. Teams of reviewers
will extract data independently and in duplicate from eligible
trials and resolve discrepancies through discussion. Data
abstracted will include study characteristics (the first author,
publication year, funding source); patient and trial characteristics
such as sample size, participant demographics (age, gender,
litigation and disability status of the participants, associated co-
morbid psychological and substance status, traumatic brain
injury and first responder status such as veterans, police officers
and fire fighters); characteristics of interventions and compara-
tors (dose of pharmacological treatments, frequency for non-
pharmacologic treatments, use of other intervention such as
medications or psychotherapies during the trial).
We will extract data on the on return to work (percent patients
on partial or complete sick leave, percent patients with partial or
complete functional recovery). We will also extract data on the
PTSD symptoms such as reported with clinician-administered
PTSD scale (CAPS),[41–43] PTSD checklist[44] or any other
validated scales, quality of life such as short-form 36 with
Physical (PCS) and mental (MCS) component summaries,[45] or
any other validated quality of life scale such as the World Health
Organization Quality of Life Questionnaire,[46] The Quality of
Life Enjoyment and Satisfaction Questionnaire[47]; functional
impairment with Sheehan’s disability scale,[48] and social and
occupational impairment with any validated scale such as social
adjustment scale.
If an individual trial reports more than 1 outcome in a common
domain (eg, return to work), we will select only 1 outcome per
domain based on the following criteria:
(1) most commonly used outcome measure across eligible trials;
(2) most validated outcome; or
(3) most precise estimate of treatment effect.
After consulting with our expert panel members, the CAPS will
be preferred over any other scale for assessing PTSD symptoms.
In the case of multiple follow-ups, we will collect data on the
longest follow-up.
2.4. Risk of bias assessment
Reviewers will assess risk of bias among the eligible studies using
the Cochrane risk of bias instrument that has modified response
options of “definitely or probably yes” – considered as low risk of
bias – or “definitely or probably no” – considered as high risk of
bias.[49]Wewill evaluate the following risk of bias issues: random
sequence generation, allocation concealment, blinding of study
participants, personnel, outcome assessors, and data analysts;
selective reporting, and incomplete outcome data (>20%missing
participant’s data).[50] We will assess risk of bias for each
outcome separately on a component-by-component basis.[51]
2.5. Data synthesis
We will do drug adjudication to collapse similar interventions or
drugs belonging to the same class into 1 treatment node. For
dichotomous outcomes (eg, percent patients on partial or
complete sick leave, percent patient with partial or complete
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functional recovery), we will calculate relative risk and absolute
risk (using baseline risk estimates from the control arm of eligible
studies), and the associated 95% confidence intervals (CIs) for
outcomes. For studies reporting continuous outcomes (eg, PTSD
symptom severity, quality of life such as SF-36 (PCS and MCS),
disability, social, and occupational impairment when the same
instrument is used, we will calculate the weighted mean
difference, and the associated 95% CIs. For trials that use
different instruments for the same underlying construct such as
functional recovery, we will convert all outcomes to a common
instrument based on the recommendations by Thorlund et al.[52]
We will contact study authors in case data is not completely
reported or will use methods suggested by Cochrane hand-
book[53] and Hozo et al[54] to impute missing standard deviations
when P-values, t-values, CIs, range, or standard errors (SEs) are
reported in articles.
2.6. Methods for direct comparisons
We will perform standard pairwise meta-analyses using the
DerSimonian–Laird random-effects model for all outcomes with
at least 2 studies.[55] We will determine statistical heterogeneity
using the Q statistic and I2. For each direct comparison, we will
report study and participant characteristics, risk of bias findings,
and pooled estimates for outcomes of interest.
2.7. Methods for multiple treatment comparisons (NMA)
To assess the comparative effectiveness of competing treatments,
we will perform random-effects NMA using the frequentist
approach.[56–59]
Although the assumptions for NMA are similar to conven-
tional meta-analysis, key extra assumptions are transitivity (there
are no effect modifiers influencing the indirect comparisons) and
coherence, (direct and indirect effect estimates are similar).[60]We
will identify incoherence comparing direct evidence (ie, estimates
from pairwise comparisons) with indirect evidence (ie, estimates
form network meta-analysis) using the node splitting method. In
this approach, the incoherence will be assessed locally within
each closed loop of the network separately as the difference
between direct and indirect estimates for a specific comparison in
the loop.[56–57] We will use a Wald test to test any statistical
difference between the direct and the indirect estimates.[57]
We will report our findings with probability statements of
intervention effects. Probability rankings allow us to report a
chance percentage of which interventions rank higher; however,
simplifying the results of a network down to probabilities can
lead to misinterpretations, specifically, when particular compar-
isons (ie, nodes) are not well-connected and/or when certainty in
evidence varies between comparisons. Following display of the
rank probabilities using rankogram, we will use the SUCRA to
aid in the interpretation of relative effect of the interventions; an
intervention with a SUCRA value of 100 is certain to be the best,
whereas an intervention with 0 is certain to be the worst.[52] We
will use STATA (StataCorp, Release 15.1, College Station, TX)
for statistical analyses.
2.8. Certainty (quality) of evidence
We will use the GRADE approach to rate the certainty in
evidence of direct, indirect, and network estimates[61–64] on an
outcome-by-outcome basis that classifies evidence as “high,”
“moderate,” “low,” or “very low.” The starting point for
certainty in estimates from randomized trials is high, but maybe
rated down based on limitations in risk of bias, imprecision,
inconsistency, and indirectness, and publication bias.[63]
We will follow detailed guidance that the GRADE working
group has provided for rating the quality of treatment effect
estimates from network meta-analysis.[62] In brief, the rating
consists of 4 steps: first, we will present direct and indirect
treatment estimates for each comparison of the evidence network.
The direct estimate of effect is provided by a head-to-head
comparison (trials of A vs B), and the indirect estimate is provided
by 2 or more head-to-head comparisons that share a common
comparator (for example, we infer the effects of A vs B from trials
of A vs C and trials of B vs C). Second, we will rate the quality of
each direct and indirect effect estimate; third, we will present the
NMA estimate for each comparison of the evidence network and
finally, we will rate the quality of each NMA effect estimate.
We will base hierarchy of the treatment options in the NMA
according to 3 categories:
(1) those that are clearly superior;
(2) those with intermediate effectiveness, and
(3) those that are inferior.
Treatments no better than placebo will be categorized in the
lowest tier; treatments better thanplacebowill be categorized in the
intermediate tier; whereas those superior to at least 1 tier 1
treatment will be judged superior. Furthermore, treatments will be
categorized according to the quality of evidence such as high and
moderate versus loworvery low. Interventionswithhighquality or
moderate evidence will be ranked as either “among the most
effective,” “inferior to the most effective/superior to the least
effective,” or “among the least effective.” Interventions supported
by low or very low quality evidence will be ranked into the same 3
categories but prefacedwith“maybe” to acknowledge the reduced
confidence in supporting evidence (eg, “may be among the most
effective”) and will be presented separately from those supported
by moderate or high quality evidence.
We will assess small study effects in direct comparisons using
theHarbord test for dichotomous outcomes and the Egger test for
continuous outcome when at least 10 studies are available.[62,64]
2.9. Subgroup and sensitivity analyses
We will test 7 a priori hypotheses to explain variability between
studies:
(1) patients in receipt of disability benefits and/or involved in
litigation will show smaller effects than those not so involved;
(2) trials at high risk of bias will show larger effects compared to
trials at low risk of bias;
(3) trials with longer follow-up will show smaller treatment
effects;
(4) trials that enrolled patients formally diagnosed with PTSD
according to validated criteria (eg, DSM-III, DSM IV, DSM
IV-R, DSM-5, CAPS, or symptom severity measures) will
show smaller effects than trials that do not require formal
diagnosis;
(5) military and first-responder samples with PTSD will show
smaller effects than civilian samples;
(6) patients with PTSD and co-morbid substance abuse will show
smaller effects than patients with PTSD without co-morbid
substance abuse;
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(7) patients with PTSD and co-morbid traumatic brain injury will
show smaller effects than patients with PTSD without co-
morbid traumatic brain injury.
We have an additional a-priori to explore the small study effect
we will run network meta-regression based on the SE.
2.10. Patient and public involvement
We have engaged an individual living with PTSD to help inform
our research design, and when our review is completed we will
ask them to assist in the interpretation and reporting of our
findings. We plan to disseminate the results of our review to
organizations supporting patients with PTSD, including Home-
wood Health and the Workers Compensation Board of
Manitoba.
3. Discussion and knowledge translation
The results of our NMA will help clinicians and inform patients
with PTSD about their therapeutic options, and facilitate
informed health management decisions. The results of our
review will be of interest to a broad audience including patients
with PTSD, physicians, mental health clinicians, and third party
payors – including insurers and compensation boards. Our
reviewwill identify key areas of future research andwill provide a
framework for conducting large systematic reviews involving
indirect comparisons.
Our proposed review has several strengths. First, we will
explore all currently available nonpharmacological and phar-
macological treatment options for PTSD reported among eligible
trials. Second, we will update the search to present date. Third,
we will use the GRADE approach to evaluate the quality of
evidence supporting treatment effects. Fourth, we will ensure
interpretability by presenting risk differences and measures of
relative effect for all pooled outcomes, and by presenting our
findings with GRADE evidence profiles. Moreover, in order to
explore the heterogeneity in our effect estimates, we have set 7 a-
priori hypotheses andwill conduct meta-regression and subgroup
analyses consistent with best current practices.
The possible limitations of our review include the potential
shortcomings of primary studies such as the presence of
publication bias, high heterogeneity, and poor quality of
reporting. Another likely limitation, unique to multiple treatment
comparison meta-analyses, will be the nature of available
treatment comparisons to build robust networks for our analyses.
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